Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery
This study is currently recruiting participants.
Verified by Biopure Corporation, May 2008
First Received: March 9, 2006   Last Updated: May 15, 2008   History of Changes
Sponsored by: Biopure Corporation
Information provided by: Biopure Corporation
ClinicalTrials.gov Identifier: NCT00301535
  Purpose

The purpose of this study is to determine if Hemopure® will enhance tissue preservation during Cardiopulmonary Bypass surgery.


Condition Intervention Phase
Coronary Artery Disease
Drug: HBOC-201 (hemoglobin glutamer-250 bovine)
Phase II

MedlinePlus related topics: Coronary Artery Disease Surgery
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Enhancement of Tissue Preservation During Cardiopulmonary Bypass With HBOC-201 (Registry Study)

Further study details as provided by Biopure Corporation:

Primary Outcome Measures:
  • Rate of peak CK-MB elevation ≥ 5X upper limit of normal [ Time Frame: Baseline; Peri-op; Days 1,2,3 post procedure; Discharge or Day 6 post procedure(whichever is earlier) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • MACE @ discharge and 30 days post surgery; Change in renal function; Renal failure; Increased Cardiac Troponin T; Death rate; MI/stroke; Supplemental RBC transfusions; Total units RBC and HBOC-201; Intra Aortic Balloon Pump use, pump time; New onset CHF [ Time Frame: Duration of the study ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 60
Study Start Date: February 2006
Estimated Study Completion Date: September 2008
Estimated Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental Drug: HBOC-201 (hemoglobin glutamer-250 bovine)
HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
2: No Intervention

Detailed Description:

The primary objective is to determine the safety and feasibility of administering Hemopure® (HBOC-201) to reduce myocardial necrosis, as measured by CK-MB enzyme elevation, and enhance tissue preservation during cardiopulmonary bypass.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is between the ages of 18 and 80.
  • Subject is an acceptable candidate for CABG.
  • Subject is scheduled for CABG (without planned valvular repair or replacement) by cardiopulmonary bypass.
  • Subject signs informed consent
  • Subject and the treating physician agree that subject can comply with all study procedures and follow-up visit at time of subject screening.

Exclusion Criteria:

  • Pre-operative myocardial infarction, defined as CK-MB level > 2 times upper limit of normal 24 hours prior to CABG surgery.
  • Renal failure defined as serum creatinine greater 220 µmol/L
  • Subject has an ejection fraction ≤ 30% (as measured by Echocardiography within 30 days of study enrollment).
  • Active infection.
  • History of prior stroke within last six months or history of prior stroke with residual neurological deficit.
  • Transient Ischemic attack within last 6 months.
  • Subject has a history of coagulopathy.
  • Subject is pregnant or currently breastfeeding.
  • History of allergy to beef products.
  • Pre-operative cardiogenic shock defined as cardiac index ≤ 1.8.L/min/m2 despite the use of vasopressors.
  • Underlying medical conditions that would limit subject's life expectancy to less than 12 months.
  • Severe pulmonary disease [based upon clinical diagnosis or pulmonary function tests (FEV <1 liter), if available] that may interfere with weaning subject from ventilator.
  • History of acute central nervous disorder (e.g., seizure or traumatic injury).
  • Severe hypertension (≥ 160/90 mm Hg) that cannot be medically controlled despite treatment with two antihypertensive therapies.
  • Severe liver dysfunction as defined by total bilirubin ≥ 51 µmol/L or 2 times the site normal limit of AST or ALT activity.
  • Subject has systemic mastocytosis.
  • Subject has any condition that predisposes the subject to systemic mast cell degranulation or hypersensitivity reactions or a history of severe allergic reactions to drugs or environmental allergens.
  • Subject has participated in another investigational drug, biologic or device study within 30 days prior to study enrollment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00301535

Contacts
Contact: Tiana Gorham tgorham@biopure.com

Locations
Greece
Thessaloniki Heart Institute - St. Luke's Hospital Recruiting
Thessaloniki, Greece, 552 36
Contact: Julia Tzelepi, MD         ktzelepipal@yahoo.gr    
Principal Investigator: Antonis Pitsis, MD            
South Africa
Milpark Hospital Recruiting
Johannesburg, South Africa
Contact: Ronel Snyman         research.jhb@mweb.co.za    
Principal Investigator: Martin Sussman, MD            
Sub-Investigator: Christopher A Hammond, MD            
United Kingdom, Oxfordshire
Oxford Heart Centre - John Radcliffe Hospital Recruiting
Headington, Oxfordshire, United Kingdom, OX3 9DU
Principal Investigator: Stephen Westaby, MD            
Sponsors and Collaborators
Biopure Corporation
Investigators
Study Director: A. Gerson Greenburg, MD, Ph.D Biopure Corporation
  More Information

No publications provided

Responsible Party: Biopure ( Biopure )
Study ID Numbers: BIOEU003
Study First Received: March 9, 2006
Last Updated: May 15, 2008
ClinicalTrials.gov Identifier: NCT00301535     History of Changes
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency;   Greece: National Organization of Medicines;   South Africa: Medicines Control Council

Keywords provided by Biopure Corporation:
Coronary Artery Bypass Graft
memory loss after cardiac surgery
side effects of bypass

Study placed in the following topic categories:
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
HBOC 201
Arteriosclerosis
Ischemia
Coronary Artery Disease
Amnesia

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Heart Diseases
Myocardial Ischemia
Hematologic Agents
Vascular Diseases
HBOC 201
Arteriosclerosis
Pharmacologic Actions
Coronary Disease
Therapeutic Uses
Blood Substitutes
Cardiovascular Diseases
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 07, 2009